MDNA55
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | MDNA55 |
| FDA Approval | No |
| Used for | Recurrent malignant gliomas |
| Clinical Trial Phase | Early phase trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified in the provided text |
| OS without | Not specified |
| OS with | Not specified in the provided text |
| PFS without | Not specified |
| PFS with | Not specified in the provided text |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2.5 |
| Toxicity Explanation | The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time. |
Notes: MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.
From Ben Williams Book: Not specified
Loading comments...
